DENVER BUSINESS JOURNAL - An Aurora research biotech landed a $6.5 million federal grant to develop a potential medication to combat alcoholism by reducing cravings and alcoholics' relapse rate.
Lohocla Research Corp. won the five-year grant from the National Institutes of Health agency called the National Institute on Alcohol Abuse and Alcoholism.
The company's drug, Nezavist, is aimed at brain receptors involved in the process of chronic alcoholics developing a tolerance to alcohol and, over time, having to drink more to achieve the same effect from alcohol.
"We foresee Nezavist serving as an important tool for alcohol-dependent individuals in their battle to quit drinking and maintain sobriety," said Dr. Boris Tabakoff, president and founder of Lohocla.
Read more at the Denver Business Journal: http://bit.ly/1NCLdGl
